| PQRST | provocative and palliative factors, quality of pain, radiation of pain, severity of pain, timing of ... |
|---|---|
| PULSES | physical condition, upper limb function, lower limb function, sensory component, excretory function,... |
| FRP | Follicle Regulatory Protein |
| IRTU | integrating regulatory transcription unit |
| MRF | Markov random field; medical record file; melanocyte-[stimulating hormone]-releasing factor; mesence... |
| type II interferon | <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease. Pharmacological action: antineoplastic agent, antiviral agents. Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced) (12 Dec 1998) |
|---|---|
| type I interferon | <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta). Pharmacological action: antineoplastic agent, antiviral agents. (12 Dec 1998) |
| fibroblast interferon | <cytokine> One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. Synonym: fibroblast interferon. Pharmacological action: adjuvants, immunologic, antineoplastic agent, antiviral agents. Chemical name: Interferon-alphaB (human leukocyte protein moiety reduced) (12 Dec 1998) |
| leukocyte interferon | <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products. It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia. A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents. See: interferon-alpha 2a, interferon-alpha 2b Synonym: leukocyte interferon. Pharmacological action: antineoplastic agent, antiviral agent. (20 Sep 2002) |
| age factors | Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from aging, a physiological process, and time factors which refers only to the passage of time. (12 Dec 1998) |
| bacteriocin factors | Bacterial plasmid's responsible for the elaboration of bacteriocins. Synonym: bacteriocin factors, bacteriocinogens. (05 Mar 2000) |
| B-cell differentiation/growth factors | Various substances, usually obtained from the supernatant of T-cell cultures, such as interleukin 4, 5, and 6. These substances are necessary for B-cell growth, maturation, and differentiation into plasma cells or B memory cells. (05 Mar 2000) |
| biological factors | Compounds made by living organisms. They have biological or physiological activities. (12 Dec 1998) |
| biotic factors | Environmental factor's or influences resulting from the activities of living organisms, as contrasted to those resulting from climatic, geological, or other factor's. (05 Mar 2000) |
| blood coagulation factors | Endogenous substances, usually proteins, that participate in the blood coagulation process. (12 Dec 1998) |
| macrophage migration-inhibitory factors | Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell. (12 Dec 1998) |
| recognition factors | Factors which effect "recognition" of target antigens by polymorphonuclear leukocytes; apparently the Fc portion of antibody molecules and the activated third component of complement (C3), for both of which phagocytes have receptor sites. (05 Mar 2000) |
| glaucoma, risk factors | If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites). (12 Dec 1998) |
| releasing factors | Hormones produced by the hypothalamus whichstimulate the release of other hormones in the pituitary gland. (09 Oct 1997) |
| resistance factors | Plasmid's carrying genes responsible for antibiotic (or antibacterial drug) resistance among bacteria (notably Enterobacteriaceae); they may be conjugative or nonconjugative plasmid's, the former possessing transfer genes (resistance transfer factor) lacking in the latter. Synonym: R factors, R plasmids, resistance factors, resistance-transferring episomes. (05 Mar 2000) |